- Home
- NRC vs EDIT Comparison
NRC vs EDIT Comparison
Compare NRC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | EDIT |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.1M | 526.4M |
| IPO Year | 1997 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NRC | EDIT |
|---|---|---|
| Price | $19.59 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 103.2K | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 4707.69 | 37.50 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $119,686,000.00 | $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $144.64 | ★ N/A |
| Revenue Growth | 1.81 | ★ 132.64 |
| 52 Week Low | $11.01 | $1.66 |
| 52 Week High | $22.79 | $4.54 |
Technical Indicators
Market Signals| Indicator | NRC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 46.74 |
| Support Level | $18.03 | $2.77 |
| Resistance Level | $22.40 | $3.27 |
| Average True Range (ATR) | 0.85 | 0.31 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 62.45 | 29.08 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.